Tumor-infiltrating plasma cell targets as a source for immunotherapies

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Tumor-infiltrating plasma cells are crucial for effective anti-cancer immunotherapy.
• Understanding the specific targets of these plasma cells can reveal new therapeutic strategies.

Purpose of the Study:

• To investigate the targets of plasma cells found in lung tumors of patients treated with anti-PD-1 immunotherapy.
• To engineer chimeric antigen receptor (CAR) T cells based on plasma cell insights for potential anti-tumor therapy.

Main Methods:

• Analysis of plasma cells from lung lesions of patients undergoing anti-PD-1 therapy.
• Identification of citrullinated proteins as targets.
• Engineering of CAR T cells utilizing single-chain variable fragments (scFv) from these plasma cells.

Main Results:

• Plasma cells from anti-PD-1 treated lung cancer patients specifically target citrullinated proteins.
• Engineered CAR T cells demonstrated specific targeting of tumor cells.
• No significant adverse effects were observed in preclinical models.

Conclusions:

• Citrullinated proteins are key targets for tumor-infiltrating plasma cells in anti-PD-1 immunotherapy.
• CAR T cells engineered with plasma cell-derived scFv offer a promising strategy for targeted cancer therapy.
• This study identifies novel therapeutic opportunities for lung cancer treatment.